Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mavroudis, D.
Right arrow Articles by Georgoulias, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mavroudis, D.
Right arrow Articles by Georgoulias, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:304-312, 2003
© 2003 European Society for Medical Oncology

Original Paper

A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors

D. Mavroudis1, P. Pappas2, C. Kouroussis1, S. Kakolyris1, S. Agelaki1, K. Kalbakis1, N. Androulakis1, J. Souglakos1, N. Vardakis1, M. Nikolaidou2, G. Samonis1, M. Marselos2 and V. Georgoulias1,+

1 Department of Medical Oncology, University General Hospital of Heraklion, Crete; 2 Department of Pharmacology, Medical School, University of Ioannina, Ioannina, Greece

Received 2 May 2002; revised 5 July 2002; accepted 18 July 2002

Background:

Gemcitabine and oxaliplatin have broad antineoplastic activity and favorable toxicity. We conducted a phase I study to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of the combination in patients with advanced solid tumors.

Patients and methods:

Sixty-eight patients with advanced stage solid tumors were enrolled. Treatment was first-line for 35% of patients, second-line for 27%, and third-line for 38%. Gemcitabine was administered at escalating doses of 1000–2000 mg/m2 as a 30-min intravenous (i.v.) infusion on days 1 and 8 and oxaliplatin at 60–130 mg/m2 as a 4-h i.v. infusion on day 8 every 21 days without growth factor support.

Results:

The MTD was defined at gemcitabine 1800 mg/m2 on days 1 and 8 and oxaliplatin 130 mg/m2 on day 8. Twelve dose levels were evaluated and DLTs occurring during the first cycle consisted of grade 4 neutropenia, grade 3 asthenia or mucositis and grade 1–3 neutropenia or thrombocytopenia resulting in treatment delays. A total of 266 cycles were administered with only one episode of febrile neutropenia and no toxic deaths. Seven (3%) and 26 (10%) cycles were complicated by grade 4 and 3 neutropenia, respectively, three (1%) and 13 (5%) by grade 4 and 3 thrombocytopenia, and eight (3%) by grade 3 anemia. The most common non-hematological toxicity was grade 2/3 asthenia observed in 23% of cycles. Responses were observed in patients with a variety of epithelial neoplasms. The pharmacokinetic study revealed no significant interaction between the two drugs.

Conclusions:

The combination of gemcitabine and oxaliplatin has excellent tolerability and promising activity in patients with advanced solid tumors. As the MTD exceeds the recommended single-agent dose for gemcitabine, and a dose–response effect has not been established, we recommend using both drugs at full doses, e.g. gemcitabine 1200–1400 mg/m2 on days 1 and 8 and oxaliplatin 130 mg/m2 on day 8 for further phase II studies.

Key words: gemcitabine, oxaliplatin, phase I, solid tumors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Theodore, F. Bidault, N. Bouvet-Forteau, M. Abdelatif, K. Fizazi, M. di Palma, P. Wibault, R. de Crevoisier, and A. Laplanche
A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
Ann. Onc., June 1, 2006; 17(6): 990 - 994.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.